- Home
- BILI vs TXMD Comparison
BILI vs TXMD Comparison
Compare BILI & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILI | TXMD |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 24.4M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BILI | TXMD |
|---|---|---|
| Price | $17.06 | $2.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $31.13 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 18.2K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $11.77 | N/A |
| Revenue Next Year | $9.59 | N/A |
| P/E Ratio | $122.37 | ★ $103.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $15.79 | $0.99 |
| 52 Week High | $36.40 | $2.95 |
Technical Indicators
Market Signals| Indicator | BILI | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 53.24 |
| Support Level | $17.13 | $1.91 |
| Resistance Level | $19.10 | $2.11 |
| Average True Range (ATR) | 0.35 | 0.04 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 26.85 | 39.03 |
Price Performance
Historical ComparisonAbout BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.